Targeting Chemotherapy of Hepatocellular Carcinoma

Arterial Administration of SMANCS/Lipiodol
  • Toshimitsu Konno
  • Hiroshi Maeda


A number of methods utilize the feeding artery of the tumor for the treatment of hepatocellular carcinoma (HCC); such methods include implantation of an infusion pump, placement of a catheter for injection into the artery, and embolization of the artery with gelatin-gel or microspheres containing anticancer agents. However, very few methods have exploited the use of lipid as a carrier and depository of an anticancer agent. Recently, we developed a procedure in which Lipiodol ultrafluid (Lipiodol) is used as a carrier of anticancer agents for injection into the feeding artery, a significant breakthrough in the treatment of solid tumors. The lipid lymphographic agent, Lipiodol, has been found to be selectively retained in HCC when injected into the hepatic artery [1]. In addition, a lipid contrast medium has various diagnostic applications, as described in this chapter. Anticancer agents, such as styrene maleic acid conjugates of neocarzinostatin (SMANCS) [2,3], mitomycin C (MMC), or aclarubicin (ACR), were dissolved into Lipiodol. As SMANCS/Lipiodol (LPD), MMC/LPD, ACR/LPD, or a mixture of these, these oily anticancer agents were administered by catheterization of the celiac or hepatic artery under X-ray monitor. Anticancer effects and the advantages of this targeting chemotherapy for HCC are described in the succeeding sections of this review.


Hepatic Artery Anticancer Agent Metastatic Liver Cancer Tumor Neovasculature Styrene Maleic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T, Yokoyama I (1983) Effect of arterial administration of high molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19:1053–1065PubMedCrossRefGoogle Scholar
  2. 2.
    Maeda H, Takeshita J, Konamaru R (1979) A lipophylic derivative of neocarzinostatin. Int J Peptide Protein Res 14:81–87CrossRefGoogle Scholar
  3. 3.
    Maeda H, Ueda M, Morinaga T, Matsumoto T (1985) Conjugation of poly (styrene-co-meleic acid) derivatives to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties. J Med Chem 28:455–461PubMedCrossRefGoogle Scholar
  4. 4.
    Folkman J (1974) Tumor angiogenesis. Adv Cancer Res 19:331–359PubMedCrossRefGoogle Scholar
  5. 5.
    Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54:2367–2374PubMedCrossRefGoogle Scholar
  6. 6.
    Maeda H, Matsumura Y, Oda T, Sasamoto K (1986) Cancer selective macromolecular therapeusis: Tailoring of an antitumor protein drug. In: Whitaker JR, Feeney RE (eds) Protein tailoring for food and medical uses. Dekker, New York, pp 353–382Google Scholar
  7. 7.
    Maeda H, Takeshita J, Kanamaru R (1979) Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent and water-soluble polymer conjugated protein. Gann 70: 601–606PubMedGoogle Scholar
  8. 8.
    Maki S, Konno T, Maeda H (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56:751–757PubMedCrossRefGoogle Scholar
  9. 9.
    Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, Konno T, Iwamoto S, Ohnishi K, Okuda K (1985) Hepatocellular carcinoma detected by iodized oil. Radiology 154: 19–24PubMedGoogle Scholar
  10. 10.
    Konno T, Tashiro S, Maeda H, Iwai K, Ogata K, Mochinaga M, Uemura K, Ishimaru Y, Miyauchi Y, Yokoyama I (1983) Treatment of hepatoma with intraarterial administration of oily anticancer agent. Gan to Kagakuryohoo (Jpn J Cancer Chemotherapy) 10:351–357 (in Japanese)Google Scholar
  11. 11.
    Jinno K, Yumoto Y, Tokuyama K, Moriwaki S, Maeda H, Konno T (1985) Continuous arterial infusion of anticancer agents and arterial injection of oily anticancer agents. Rinsho Seijin Byo 15: 1657–1665 (in Japanese)Google Scholar
  12. 12.
    Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor results in enhanced therapeutic effect and X-ray image. Cancer Res 44:2115–2122PubMedGoogle Scholar

Copyright information

© Springer Japan 1987

Authors and Affiliations

  • Toshimitsu Konno
    • 1
  • Hiroshi Maeda
    • 2
  1. 1.The First Department of SurgeryKumamoto University Medical SchoolHonjo, Kumanoto, 860Japan
  2. 2.Department of MicrobiologyKumamoto University Medical SchoolHonjo, Kumanoto, 860Japan

Personalised recommendations